Over the last 12 months, Neurocrine Biosciences insiders reported no purchases and 24 sales totaling $36.3M across SEC Form 4 filings. 100% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 28, 2026 | Norwalk Leslie VD | ▼ Sale | 1,250 | $182.01 | $228K | -44% | plan |
| Jul 10, 2026 | Delaet IngridChief Regulatory Officer · O | ▼ Sale | 4,367 | $181.02 | $791K | -21.2% | plan |
| Jul 9, 2026 | Lippoldt DarinChief Legal Officer · O | ▼ Sale | 10,000 | $179.6 | $1.8M | -15.4% | plan |
| Jul 9, 2026 | Delaet IngridChief Regulatory Officer · O | ▼ Sale | 14,571 | $178.65 | $2.6M | -47.3% | plan · 3 tranches |
| Jun 29, 2026 | Lippoldt DarinChief Legal Officer · O | ▼ Sale | 10,000 | $170.15 | $1.7M | -15.4% | plan · 3 tranches |
| Jun 5, 2026 | SHERWIN STEPHEN AD | ▼ Sale | 25,000 | $165.32 | $4.1M | -61.2% | plan · 5 tranches |
| Jun 4, 2026 | Norwalk Leslie VD | ▼ Sale | 1,250 | $168.06 | $210K | -30.6% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 3,520 | $158.59 | $558K | -13.6% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 9,521 | $157.62 | $1.5M | -26.9% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 4,216 | $156.77 | $661K | -10.6% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 5,466 | $155.46 | $850K | -12.1% | plan |
| Jun 2, 2026 | Cooke JulieChief Human Resources Officer · O | ▼ Sale | 14,214 | $154.83 | $2.2M | -24% | plan |
| Jun 1, 2026 | Onyia JudeChief Scientific Officer · O | ▼ Sale | 11,000 | $160.25 | $1.8M | -29.9% | plan |
| May 29, 2026 | Delaet IngridChief Regulatory Officer · O | ▼ Sale | 2,261 | $156.71 | $354K | -12.2% | plan |
| May 27, 2026 | Onyia JudeChief Scientific Officer · O | ▼ Sale | 11,000 | $155.53 | $1.7M | -29.9% | plan |
| May 26, 2026 | Boyer David W.Chief Corp. Affairs Officer · O | ▼ Sale | 3,888 | $156.64 | $609K | -33.3% | plan |
| Jan 16, 2026 | Gano KyleChief Executive Officer · O·D | ▼ Sale | 36,400 | $132.7 | $4.8M | -20.6% | plan · 2 tranches |
| Dec 16, 2025 | Norwalk Leslie VD | ▼ Sale | 6,190 | $152.78 | $946K | -49.8% | plan · 2 tranches |
| Dec 8, 2025 | Lippoldt DarinChief Legal Officer · O | ▼ Sale | 4,376 | $159.65 | $699K | -9.2% | plan |
| Dec 3, 2025 | LYONS GARY AD | ▼ Sale | 15,000 | $152.61 | $2.3M | -11.1% | plan |
| Nov 28, 2025 | BENEVICH ERICChief Commercial Officer · O | ▼ Sale | 5,970 | $151.74 | $906K | -11.7% | plan |
| Nov 25, 2025 | MORROW GEORGE JD | ▼ Sale | 15,000 | $143.37 | $2.2M | -68% | plan |
| Nov 5, 2025 | RASTETTER WILLIAM HD | ▼ Sale | 18,000 | $151.82 | $2.7M | -30.8% | plan |
| Nov 4, 2025 | Gano KyleChief Executive Officer · O·D | ▼ Sale | 300 | $141.97 | $43K | -0.2% | plan |
| Aug 7, 2025 | GORMAN KEVIN CHARLESD | ▼ Sale | 106,322 | $126.41 | $13.4M | -17.1% | plan |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Neurocrine Biosciences filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $NBIX feed.